Show Summary Details
Page of

Hematologic Systems 

Hematologic Systems
Chapter:
Hematologic Systems
Author(s):

Sam Gumbert

DOI:
10.1093/med/9780199381623.003.0028
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 23 October 2019

A total of 30 million blood components are transfused each year in the United States. The transfusion of red blood cells (RBCs), platelets, fresh-frozen plasma (FFP), and cryoprecipitate has the potential of improving clinical outcomes in perioperative and peripartum settings. These benefits include improved tissue oxygenation, correction of coagulopathies, reduced bleeding, and improved survivorship. This chapter discusses the use of various blood products. However, transfusions are not without risks or costs. The transmission of infectious diseases such as hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus [HIV]) is rare but exists. Additionally, non-infectious adverse reactions such as allergic reactions acute hemolytic transfusion reaction (AHTR), non-hemolytic transfusion reactions, immunosuppression, alloimmunization, and other complications are potential sequelae of blood component therapy

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.